• Other
  • Exited

Alnara Pharmaceuticals, Inc. develops and commercializes novel protein therapeutics for the treatment of metabolic diseases. The Company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Alnara’s lead product is liprotamase, a novel, non-porcine pancreatic enzyme replacement therapy, which has completed Phase 3 clinical development. Alnara was acquired by Eli Lilly in July 2010.